The Motley Fool: Bristol Myers Squibb: Low Volatility Meets High Dividend Yield
Bristol-Myers Squibb (NYSE: BMY) has considerably lagged behind the overall market, with its stock decreasing by 20% this year, while the S&P 500 index has risen by 14%. This drop can be attributed in ...
The Motley Fool: Is Bristol Myers Squibb the Best Bargain in Big Pharma?
Bristol Myers Squibb's valuation metrics show the stock is a bona fide bargain. However, valuation metrics can be misleading because most of them don't factor in growth. The stock may not be the ...
Seeking Alpha: Bristol-Myers Squibb: 'Strong Buy' As 2026 Milestones Could Bolster Its Prospects
Bristol-Myers Squibb's growth portfolio nears 60% of total revenues, growing 16% YoY, effectively offsetting patent cliff losses. Learn more on BMY stock here.
Bristol Myers Squibb (BMY) is finally showing signs of life. The stock has climbed 7.3% over the last five days, adding roughly $7 billion in market value — pushing its market cap back toward $100 ...
Drugmaker Bristol-Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing ...
Business Wire: Bristol Myers Squibb to Report Results for First Quarter 2026 on
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2026 on Thursday, . Company executives will review financial results ...
Fierce Biotech: Foundation Medicine expands Bristol Myers Squibb collaboration with new diagnostic target
Roche’s Foundation Medicine is deepening its longstanding ties with Bristol Myers Squibb as the companies team up on a new target. | Roche’s Foundation Medicine is deepening its longstanding ties with ...